Answers are grounded in this paper and cite their sources.
8554 Background: Ipilimumab is a fully human monoclonal antibody that potentiates immunity by blocking interactions between CTLA-4 and CD80/CD86. Ipilimumab has shown survival benefit in subjects with previously treated metastatic melanoma (Hodi et al, NEJM 2010;363:711). Diarrhea/colitis (D/C) are adverse events that occur with ipilimumab which could develop into serious life threatening complications such as bowel perforation. A gastrointestinal management guideline has been developed as a reference for managing D/C events. The objective of this analysis was to assess the effectiveness of a protocol specified treatment algorithm on the management of D/C. Methods: This was an event level analysis. A total of 687 D/C events from 5 studies in which 511 subjects received ipilimumab 3 mg/kg every 3 wks for 4 doses, and 325 subjects received 10 mg/kg. Results: Subjects in the 3 mg/kg cohort reported 370 D/C events. Guidance for Grade 1 (g1) diarrhea was to treat symptomatically without immunosuppressives (IS) unless it persisted beyond 5 days: 64% of the events were g1, 18% prompted treatment with IS. Of the g1 events that were managed with IS, 67% resolved; of those that did not receive IS, 87% resolved. Guidance for g2 diarrhea was to treat symptomatically, with budesonide, or with corticosteroids if symptoms persist for 3-5 days or worsen. G2 D/C occurred in 22% of all events; 46% were treated with IS; median time to first IS was 3 days. The majority of g2 events resolved or improved regardless of IS. Systemic corticosteroids were recommended for g≥3 D/C. Resolution/downgrading of symptoms occurred in 90% of g≥3 events after IS. Median time to resolution was 2 wks and median time to downgrade was 1 wk. Initiation of IS within 5 days from onset of an event led to faster resolution of symptoms compared to IS after 5 days. 13% of the events were g≥3; 86% were managed with systemic corticosteroids and median time to first dose was 1 day. Conclusions: When the use of protocol specified guidance was followed appropriately it led to resolution of D/C during ipilimumab treatment. The majority of high grade colitis events were treated with systemic steroids. Rapid institution of IS (within 5 days) led to faster resolution of symptoms.
No takes yet. Share an insight, caveat, or question.
O’Day et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: